Application of Physiologically Based Pharmacokinetic Modeling to Inform Dose Selection of Mezigdomide in a Phase I Drug–Drug Interaction Study

Ähnliche Einträge

• Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug–Drug Interactions
  von: Cornelius Cilliers, et al.
  Veröffentlicht: (2024)
• Comprehensive Evaluation of OATP‐ and BCRP‐Mediated Drug–Drug Interactions of Methotrexate Using Physiologically‐Based Pharmacokinetic Modeling
  von: Sejung Hwang, et al.
  Veröffentlicht: (2024)
• Viral Kinetics Model of SARS‐CoV‐2 Infection Informs Drug Discovery, Clinical Dose, and Regimen Selection
  von: Allison M. Claas, et al.
  Veröffentlicht: (2024)
• Physiologically Based Pharmacokinetic Modeling to Investigate the Disease‐Drug–Drug Interactions between Voriconazole and Nirmatrelvir/Ritonavir in COVID‐19 Patients with CYP2C19 Phenotypes
  von: Peile Wang, et al.
  Veröffentlicht: (2024)
• Effects of GLPG3970 on Sulfasalazine and Methotrexate Pharmacokinetics in Healthy Adults: Two Open‐Label, Phase I, Drug–Drug Interaction Studies
  von: Mariska van der Plas, et al.
  Veröffentlicht: (2024)